4Thatcher N, Chang A, Parrikh P, et al. Gifitinib plus best supportive care in previously treated patients with refractory advanced nonsmall-cell lung cancer: results from a randomised, placebo-controlled,muhicentre study( Iresaa Survival Evaluation in Lung Cancer). Lancet,2005,366 : 1527-1537.
6Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002.CA Cancer J Clin,2005,55(2):74-108.
7Govindan R,Page N,Morgensztem D,et al.Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance,epidemiologic,and end results database.J Clin Oncol,2006,24 (28):4539-4544.
8Fukuoka M,Yano S,Giaccone G,et al.Multi-insitution a randomizedphase Ⅱ trail of gefitinib for previously treated patients with advancednon-small-cell lung cancer(The IDEAL1 Trial).J Clin Oncol,2003,21 (12):2237-2246.
10ParkK,GotoK.A Review of the benefit-risk profile ofgefitinib inAsianpatients with advanced non-small-cell lung cancer. Current MedicalResearch and Opinion . 2006
